Aprea Therapeutics (APRE)CFO bought ~$5.1K

~$5.1K

Approx. value · 5,700 sh @ $0.89

33K

Holds after · shares reported

Traded

Jan 30, 2026

Filed

Feb 2, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 8, 2025Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
2. Dec 10, 2025Insider · 2 peopleInsiders: 2 purchases (~$31K)
3. Jan 23, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On January 23, 2026, Aprea Therapeutics, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital…”
4. Jan 28, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 2 more items)
5. Jan 30, 2026 · this disclosureInsider · Bought outside the usual windowCFO purchased ~$5.1K of APRE shares in the open market

What came next

1. Jan 30, 2026Insider · Bought outside the usual windowCEO purchased ~$25K of APRE shares in the open market
2. Mar 16, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
3. Mar 30, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 2 more items)
4. May 13, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Aprea Therapeutics

OQRO holds no insider, Congress, fund or contract record for Aprea Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its APRE page.

Other recent filings by John P. Hamill, SrVP/CFO/Prin Fin & Acct Ofcr

• SEC Form 4 at Aprea Therapeutics (APRE)Dec 11, 2025
• SEC Form 4 at Aprea Therapeutics (APRE)Oct 16, 2024
• SEC Form 4 at Aprea Therapeutics (APRE)Oct 15, 2024

The full history of John P. Hamill, SrVP/CFO/Prin Fin & Acct Ofcr is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Aprea Therapeutics

• SEC Form 4Feb 2, 2026
• SEC Form 4Dec 11, 2025
• SEC Form 4Dec 11, 2025
• SEC Form 4Apr 4, 2025
• SEC Form 4Apr 4, 2025
• SEC Form 4Oct 25, 2024

Everything OQRO holds on this company is on its APRE page.